Erenumab

Erenumab Reduces Monthly Migraine Days in Patients With Treatment-Resistant Migraine

Erenumab Reduces Monthly Migraine Days in Patients With Treatment-Resistant Migraine

By

Patients with difficult-to-treat migraine were randomly assigned 1:1 to either 140 mg erenumab or placebo.

FDA Approves Aimovig for Migraine Prevention

FDA Approves Aimovig for Migraine Prevention

By

The first-in-class migraine prevention drug will be available to patients within 1 week of the approval.

Erenumab Shown to Reduce Headache Days for Patients with Episodic Migraine

Erenumab Shown to Reduce Headache Days for Patients with Episodic Migraine

By

Researchers assessed the ability of erenumab to decrease the mean number of acute headache days in patients with episodic migraine.

Once-Monthly Erenumab Injections May Be Effective for Episodic Migraine Prophylaxis

Once-Monthly Erenumab Injections May Be Effective for Episodic Migraine Prophylaxis

By

A monthly subcutaneous injection of 70 mg erenumab may represent an effective prophylactic treatment for episodic migraine.

Erenumab Shows Promise in Treatment-Resistant Migraine

Erenumab Shows Promise in Treatment-Resistant Migraine

By

A recent study evaluated the safety and efficacy of erenumab in patients with episodic migraine who had experienced 2 to 4 previous preventive treatment failures, due to lack of efficacy or intolerable side effects.

Erenumab for Episodic Migraine Prophylaxis: Current Evidence

Erenumab for Episodic Migraine Prophylaxis: Current Evidence

By

The monoclonal antibody erenumab has shown favorable results regarding efficacy and safety for the prevention of migraine.

Aimovig Under Review for Migraine Prophylaxis

Aimovig Under Review for Migraine Prophylaxis

By

The FDA has accepted for review the Biologics License Application for Aimovig for migraine prophylaxis in patients experiencing more than 4 migraine days per month.

Anti-CGRP Receptor Antibody Erenumab Reduces Monthly Migraine Days

Anti-CGRP Receptor Antibody Erenumab Reduces Monthly Migraine Days

By

In a phase 3 trial, treatment with erenumab reduced migraine frequency, monthly migraine days, and migraine medication use in patients with episodic migraine.

Sign Up for Free e-Newsletters